Aesthetic Medical International Holdings Group (PAIYY) AI Stock Analysis

• Market Cap: $2.53M
• Dividend Yield: N/A
• Average Volume (3M): 576.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.66
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,286
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 48,687,584
• 10 Day Avg. Volume: 50
• 30 Day Avg. Volume: 576
• PEG Ratio: 0.04
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 0.05
• P/FCF Ratio: 0.73
• Enterprise Value/Market Cap: 68.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.09 ▼(-70.69% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is driven primarily by mixed financial performance: improving revenue, sharply reduced operating losses, and stronger cash flow are offset by ongoing net losses and a highly leveraged balance sheet. Technicals add downside risk with price below key moving averages and negative MACD, while valuation cannot be meaningfully assessed due to missing P/E and dividend yield.

Positive Factors

Revenue Growth

A 10.7% revenue increase indicates durable demand expansion and better market traction for the company's services. Over a 2-6 month horizon, sustained top-line growth can support fixed-cost absorption, improve operating leverage, and create a clearer path to sustained profitability if cost discipline continues.

Narrowing Operating Losses

Substantial reduction in EBIT losses demonstrates effective cost control and improved operational efficiency. This durable improvement reduces cash burn, shortens runway, and suggests management can convert revenue growth into closer-to-breakeven operations if the trend persists across upcoming quarters.

Improved Cash Generation

Growing positive free cash flow and operating cash flow exceeding net income show real cash generation beyond accounting profits. This strengthens liquidity, supports debt servicing and working capital, and materially improves the firm's financial flexibility over the medium term if cash conversion remains consistent.

Negative Factors

Highly Leveraged Balance Sheet

An equity ratio of 6.3% signals heavy reliance on debt financing and a thin equity cushion. This structural leverage increases sensitivity to interest costs, restricts strategic options, and heightens refinancing and solvency risk over the medium term, especially if cash generation underperforms expectations.

Ongoing Net Losses

Despite improved EBIT, the company remains unprofitable on a net basis, indicating non-operating costs or residual losses persist. Continued negative net margins require sustained revenue expansion or further cost reductions to reach durable profitability and reduce the need for external financing.

Small Equity Base / Liability Concentration

A small equity base paired with significant liabilities magnifies downside risk from asset write-downs or operational shocks. It also increases dilution risk if capital raises are needed and limits borrowing capacity, creating a lasting constraint on strategic investments and resilience.

Aesthetic Medical International Holdings Group Business Overview & Revenue Model

Company Description

Aesthetic Medical International Holdings Group (PAIYY) is a leading provider of aesthetic medical services and products in China. The company operates a network of outpatient clinics that offer a wide range of non-surgical aesthetic procedures, including skin rejuvenation, body contouring, and cosmetic injections. PAIYY also engages in the research, development, and distribution of aesthetic medical devices and products, catering to the growing demand for cosmetic enhancements in the region.

How the Company Makes Money

The company generates revenue primarily through its aesthetic medical services offered at its clinics. This includes fees from various non-invasive procedures and treatments that clients seek for cosmetic enhancements. Additionally, PAIYY earns income from the sale of aesthetic medical devices and products, which are either developed in-house or sourced from partnerships with other manufacturers. The company may also benefit from strategic alliances or collaborations with other healthcare providers, enhancing its service offerings and expanding its market reach. Through these diversified revenue streams, PAIYY capitalizes on the increasing consumer interest in aesthetic treatments, contributing significantly to its overall earnings.

Aesthetic Medical International Holdings Group Financial Statement Overview

Summary

Mixed fundamentals: revenue grew 10.7% and EBIT losses narrowed significantly (from -48.81M to -4.04M), with improving free cash flow and solid operating cash flow. However, profitability remains negative and the balance sheet is highly leveraged with a very low equity ratio (6.3%), increasing financial risk.

Income Statement

The company has shown improvement in reducing its operating losses, with EBIT rising from -48.81 million to -4.04 million. Revenue growth is evident with a 10.7% increase from the previous year. However, the net profit margin remains negative, indicating ongoing challenges in achieving profitability. Continued focus on cost management is needed.

Balance Sheet

The company's financial stability is concerning, with a high debt-to-equity ratio due to significant liabilities overshadowing the small equity base. The equity ratio is low at 6.3%, indicating heavy reliance on debt financing. However, there have been improvements in stockholders' equity and asset management, which is a positive sign.

Cash Flow

The cash flow situation has improved, with a positive free cash flow growing significantly from the previous year. The operating cash flow is healthy and exceeds net income, indicating strong cash generation capabilities despite net losses. Continued improvement in free cash flow sustainability is crucial.

Breakdown	Dec 2024	Dec 2023	Mar 2023	Dec 2021	Mar 2021
Income Statement
Total Revenue	755.67M	682.59M	670.09M	645.59M	901.57M
Gross Profit	337.79M	322.05M	355.59M	269.50M	544.78M
EBITDA	73.33M	25.31M	-11.05M	-554.95M	-123.90M
Net Income	-19.95M	-37.43M	-76.25M	-586.62M	-235.48M
Balance Sheet
Total Assets	486.22M	560.66M	546.37M	576.94M	1.04B
Cash, Cash Equivalents and Short-Term Investments	42.84M	62.34M	12.16M	39.29M	44.38M
Total Debt	179.30M	244.55M	393.10M	405.91M	460.79M
Total Liabilities	476.88M	527.03M	672.25M	763.36M	612.35M
Stockholders Equity	30.46M	48.89M	-113.66M	-156.67M	390.90M
Cash Flow
Free Cash Flow	48.88M	18.83M	-76.80M	17.65M	-46.01M
Operating Cash Flow	79.67M	74.29M	-75.13M	51.09M	-843.00K
Investing Cash Flow	-30.32M	-52.25M	3.11M	-11.53M	-127.37M
Financing Cash Flow	-68.55M	29.06M	45.55M	-45.23M	17.70M

Aesthetic Medical International Holdings Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAIYY, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.08, and above the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 31.00 is Neutral, neither overbought nor oversold. The STOCH value of 9.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAIYY.

Aesthetic Medical International Holdings Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NCNA	46 Neutral	$8.95M	-0.01	-179.40%	―	―	94.52%
HSCS	46 Neutral	$8.45M	-0.39	-220.42%	―	-41.03%	35.71%
PAIYY	45 Neutral	$2.53M	―	-76.57%	―	―	―
TNMG	41 Neutral	$7.77M	-0.05	-164.27%	―	4.59%	-920.22%